BOSTON SCIENTIFIC CORPORATION (BSX) Gross Margin
- Gross margin · 12 months: Value 69.93%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 69.93% | Gross profit / revenue. Period ending 2026-06-30. $14.68B ÷ $21.00B × 100 ≈ 69.93% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 14.68B USD | Gross Profit |
| Revenue | 21.00B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 6.32B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $14.68B | $21.00B | $6.32B | 69.93% |
| 2026-03-31 | $14.26B | $20.61B | $6.36B | 69.17% |
| 2025-12-31 | $13.85B | $20.07B | $6.22B | 69.01% |
| 2025-09-30 | $13.27B | $19.35B | $6.08B | 68.58% |
| 2025-06-30 | $12.63B | $18.49B | $5.87B | 68.27% |
| 2025-03-31 | $12.05B | $17.55B | $5.50B | 68.66% |
| 2024-12-31 | $11.49B | $16.75B | $5.26B | 68.61% |
| 2024-09-30 | $10.97B | $15.91B | $4.94B | 68.97% |
| 2024-06-30 | $10.50B | $15.23B | $4.73B | 68.97% |
| 2024-03-31 | $10.20B | $14.71B | $4.51B | 69.32% |
| 2023-12-31 | $9.90B | $14.24B | $4.34B | 69.49% |
| 2023-09-30 | $9.55B | $13.76B | $4.21B | 69.41% |
| 2023-06-30 | $9.31B | $13.40B | $4.09B | 69.51% |
| 2023-03-31 | $9.01B | $13.04B | $4.04B | 69.03% |
| 2022-12-31 | $8.73B | $12.68B | $3.96B | 68.81% |
| 2022-09-30 | $8.65B | $12.57B | $3.92B | 68.83% |
| 2022-06-30 | $8.49B | $12.33B | $3.84B | 68.87% |
| 2022-03-31 | $8.39B | $12.16B | $3.77B | 68.99% |
| 2021-12-31 | $8.18B | $11.89B | $3.71B | 68.78% |
| 2021-09-30 | $7.73B | $11.47B | $3.74B | 67.39% |
| 2021-06-30 | $7.49B | $11.20B | $3.71B | 66.88% |
| 2021-03-31 | $6.57B | $10.12B | $3.55B | 64.90% |
| 2020-12-31 | $6.45B | $9.91B | $3.46B | 65.05% |
| 2020-09-30 | $6.79B | $10.11B | $3.32B | 67.21% |
| 2020-06-30 | $6.93B | $10.16B | $3.22B | 68.27% |
| 2020-03-31 | $7.59B | $10.79B | $3.19B | 70.41% |
| 2019-12-31 | $7.62B | $10.73B | $3.12B | 70.98% |
| 2019-09-30 | $7.40B | $10.39B | $2.99B | 71.19% |
| 2019-06-30 | $7.19B | $10.08B | $2.89B | 71.34% |
| 2019-03-31 | $7.07B | $9.94B | $2.87B | 71.12% |
| 2018-12-31 | $7.01B | $9.82B | $2.81B | 71.37% |
| 2018-09-30 | $6.91B | $9.67B | $2.76B | 71.49% |
| 2018-06-30 | $6.78B | $9.50B | $2.72B | 71.34% |
| 2018-03-31 | $6.65B | (m) | $2.62B | (m) |
| 2017-12-31 | $6.46B | $9.05B | $2.59B | 71.34% |
| 2017-09-30 | $6.29B | (m) | $2.54B | (m) |
| 2017-06-30 | $6.22B | (m) | $2.50B | (m) |
| 2017-03-31 | $6.08B | (m) | $2.50B | (m) |
| 2016-12-31 | $5.96B | (m) | $2.42B | (m) |
| 2016-09-30 | $5.79B | (m) | $2.38B | (m) |
| 2016-06-30 | $5.63B | (m) | $2.32B | (m) |
| 2016-03-31 | $5.45B | (m) | $2.23B | (m) |
| 2015-12-31 | $5.30B | (m) | $2.17B | (m) |
| 2015-09-30 | $5.23B | (m) | $2.16B | (m) |
| 2015-06-30 | $5.17B | (m) | $2.17B | (m) |
| 2015-03-31 | $5.18B | (m) | $2.19B | (m) |
| 2014-12-31 | $5.17B | (m) | $2.21B | (m) |
| 2014-09-30 | $5.12B | (m) | $2.21B | (m) |
| 2014-06-30 | $5.05B | (m) | $2.17B | (m) |
| 2014-03-31 | $5.02B | (m) | $2.13B | (m) |
| 2013-12-31 | $4.97B | $7.14B | $2.17B | 69.56% |
| 2013-09-30 | $4.93B | $7.13B | $2.20B | 69.13% |
| 2013-06-30 | $4.88B | $7.13B | $2.25B | 68.45% |
| 2013-03-31 | $4.85B | $7.14B | $2.30B | 67.86% |
| 2012-12-31 | $4.90B | $7.25B | $2.35B | 67.60% |
| 2012-09-30 | $4.85B | $7.28B | $2.43B | 66.64% |
| 2012-06-30 | $4.87B | $7.42B | $2.55B | 65.63% |
| 2012-03-31 | $4.90B | $7.56B | $2.66B | 64.84% |
| 2011-12-31 | $4.96B | $7.62B | $2.66B | 65.11% |
| 2011-09-30 | $5.12B | $7.78B | $2.66B | 65.81% |
| 2011-06-30 | $5.22B | $7.82B | $2.60B | 66.72% |
| 2011-03-31 | $5.20B | $7.77B | $2.57B | 66.97% |
| 2010-12-31 | $5.21B | $7.81B | $2.60B | 66.71% |
| 2010-09-30 | $5.24B | $7.88B | $2.65B | 66.41% |
| 2010-06-30 | $5.34B | $7.99B | $2.65B | 66.78% |
| 2010-03-31 | $5.51B | $8.14B | $2.63B | 67.66% |
| 2009-12-31 | $5.61B | $8.19B | $2.58B | 68.54% |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) |
| 2008-12-31 | $5.58B | $8.05B | $2.47B | 69.33% |
| 2008-09-30 | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) |
| 2007-12-31 | $6.01B | $8.36B | $2.34B | 71.98% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |